# The Evolving Landscape of Malaria Prevention Strategies: A Review of Recent Developments

**Authors:** Yathavi Charavanamuttu, Akosua Agyeman Wamba, Andrew W. Taylor-Robinson, Temi Lampejo

PMC · DOI: 10.3390/pathogens15020137 · Pathogens · 2026-01-26

## TL;DR

This review discusses recent developments in malaria prevention, highlighting challenges and new strategies to combat the disease.

## Contribution

The paper synthesizes current and emerging prevention strategies, emphasizing the need for adaptive approaches to achieve malaria elimination.

## Key findings

- Insecticide-treated nets and indoor residual spraying are still key but face resistance challenges.
- Vaccines like RTS,S/AS01 and R21/Matrix-M show promise in reducing severe malaria and mortality.
- New approaches such as monoclonal antibodies and genetically modified mosquitoes are emerging as potential solutions.

## Abstract

Malaria continues to impose a devastating disease burden globally despite control efforts spanning decades. Its elimination has been hindered by parasite and vector complexity and emerging drug and insecticide resistance, along with unremitting barriers to uptake of preventative strategies largely driven by social inequities, cost constraints, and logistical challenges in implementation. This review synthesises current and emerging prevention strategies, including vector control, chemoprevention and immunoprophylaxis. Insecticide-treated nets and indoor residual spraying remain cornerstones of vector control, although their effectiveness is increasingly compromised by widespread insecticide resistance. Chemoprevention, including intermittent preventive treatment in pregnancy and seasonal malaria chemoprevention in children, has proven highly efficacious, yet uptake remains below WHO targets and concerns about drug resistance remain. Recent advances in vaccines, notably RTS,S/AS01 and R21/Matrix-M, represent landmark achievements, with large-scale rollouts demonstrating reductions in severe disease and mortality. Novel approaches, such as monoclonal antibodies and genetically modified mosquitoes, offer promising avenues for future prevention. However, challenges remain in ensuring equitable access, sustaining efficacy in the face of evolving parasite and vector biology, and integrating interventions into diverse health systems. This review highlights the need for adaptive, multifaceted approaches to achieve malaria elimination goals.

## Linked entities

- **Diseases:** malaria (MONDO:0005136)

## Full-text entities

- **Genes:** PLG (plasminogen) [NCBI Gene 5340] {aka HAE4}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}
- **Diseases:** shock (MESH:D012769), injury to (MESH:D014947), headaches (MESH:D006261), meningitis (MESH:D008580), P. falciparum infection (MESH:D016778), diarrhoea (MESH:D003967), pneumonia (MESH:D011014), P. vivax Malaria (MESH:D016780), cutaneous (MESH:D018366), dengue (MESH:D003715), febrile (MESH:D000071072), vomiting (MESH:D014839), convulsions (MESH:D012640), febrile illness (MESH:D005334), uncomplicated (MESH:C536333), impaired consciousness (MESH:D003244), deaths (MESH:D003643), cerebral malaria (MESH:D016779), infection (MESH:D007239), COVID-19 (MESH:D000086382), rabies (MESH:D011818), anaemia (MESH:D000743), chikungunya (MESH:D065632), renal impairment (MESH:D007674), severe (MESH:D045169), yellow fever (MESH:D015004), Malaria (MESH:D008288), zika (MESH:D000071243), mosquito infections (MESH:D000079426)
- **Chemicals:** chlorproguanil (MESH:C007030), PMD (MESH:C005804), ivermectin (MESH:D007559), mefloquine (MESH:D015767), bifenthrin (MESH:C099952), malathion (MESH:D008294), piperaquine (MESH:C034759), pyrethroid (MESH:D011722), Permethrin (MESH:D026023), 8-aminoquinoline (MESH:C080436), pyrimethamine (MESH:D011739), amodiaquine (MESH:D000655), atovaquone (MESH:D053626), chlorfenapyr (MESH:C436643), cyfluthrin (MESH:C052570), dapsone (MESH:D003622), deltamethrin (MESH:C017180), SP (MESH:C001205), pyriproxyfen (MESH:C055613), DDT (MESH:D003634), Montanide ISA-51 (MESH:C477385), 75B10 (-), S (MESH:D013455), tafenoquine (MESH:C055852), DEET (MESH:D003671), CIS43LS (MESH:C000719153), carbamates (MESH:D002219), primaquine (MESH:D011319), albendazole (MESH:D015766), piperonyl butoxide (MESH:D010882), Icaridin (MESH:C483506), alphacypermethrin (MESH:C017160)
- **Species:** Plasmodium ovale wallikeri (subspecies) [taxon 864142], Plasmodium ovale curtisi (subspecies) [taxon 864141], Plasmodium falciparum NF54 (isolate) [taxon 5843], Plasmodium yoelii (species) [taxon 5861], Mus musculus (house mouse, species) [taxon 10090], Plasmodium malariae (species) [taxon 5858], Plasmodium falciparum (malaria parasite P. falciparum, species) [taxon 5833], Homo sapiens (human, species) [taxon 9606], Plasmodium knowlesi (species) [taxon 5850], Plasmodium vivax (malaria parasite P. vivax, species) [taxon 5855], Wolbachia pipientis (species) [taxon 955], Anopheles funestus (African malaria mosquito, species) [taxon 62324]
- **Mutations:** R78C

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943406/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12943406/full.md

## References

160 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943406/full.md

---
Source: https://tomesphere.com/paper/PMC12943406